Histone deacetylase inhibition improves differentiation of dendritic cells from leukemic blasts of patients with TEL/AMLI-positive acute lymphoblastic leukemia

Journal of Leukocyte Biology

Volumn 85, Issue 3, 2009, Pages 563-573

  Schmidt, Kerstin ^a   Seeger, Karl ^b   Scheibenbogen, Carmen ^c   Bender, Roderich ^a   Abdulla, Majd ^a   Süssmilch, Sina ^a   Salama, Abdulgabar ^a   Moldenhauer, Anja ^a,c  

^a Institutes for Transfusion Medicine   (Germany)

^b Institute for Immunology   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cytokines; Cytotoxic T cells; Suberoylanilide hydroxamic acid; Vaccine; Valproic acid

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD83 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; FLT3 LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; INTERLEUKIN 3; INTERLEUKIN 4; ISOBUTYRAMID; STEM CELL FACTOR; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW CELL; BONE MARROW CULTURE; CANCER PATIENT; CELL DIFFERENTIATION; CELL TYPE; CHILD; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CULTURE TECHNIQUE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME INHIBITION; FEMALE; FETUS LIVER; FUSION GENE; GENE EXPRESSION; GENE TRANSLOCATION; GENETIC CODE; HUMAN; HUMAN CELL; IMMUNOGENICITY; LEUKEMIA CELL; LYMPHOBLAST; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; SENSITIZATION;

ANTIGEN PRESENTATION; BLAST CRISIS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; CHILD; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DENDRITIC CELLS; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; INTERFERON-GAMMA; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61549097188     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0808469     Document Type: Article

References (69)

1. Zelent, A., Greaves, M., Enver, T. (2004) Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukemia. Oncogene 23, 4275-4283.
2. Hong, D., Gupta, R., Ancliff, P., Atzberger, A., Brown, J., Soneji, S., Green, J., Colman, S., Piacibello, W., Buckle, V., Tsuzuki, S., Greaves, M., Enver, T. (2008) Initiating and cancer-propagating cells in TEL-AMLl-associated childhood leukemia. Science 319, 336-339.
3. Tsuzuki, S., Karnan, S., Horibe, K., Matsumoto, K., Kato, K., Inukai, T., Goi, K., Sugita, K., Nakazawa, S., Kasugai, Y., Ueda, R., Seto, M. (2007) Genetic abnormalities involved in t(12;21) TEL-AML1 acute lymphoblastic leukemia: analysis by means of array-based comparative genomic hybridization. Cancer Sci. 98, 698-706.
4. Rubnitz, J. E., Downing, J. R., Pui, C. H., Shurtleff, S. A., Raimondi, S. C., Evans, W. E., Head, D. R., Crist, W. M., Rivera, G. K., Hancock, M. L., Boyett, J. M., Buijs, A., Grosveld, G., Behm, F. G. (1997) TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J. Clin. Oncol. 15, 1150-1157
5. Ibid.
6. Seeger, K., von Stackelberg, A., Taube, T., Buchwald, D., Korner, G., Suttorp, M., Dorffel, W., Tausch, W., Henze, G. (2001) Relapse of TEL-AML1-positive acute lymphoblastic leukemia in childhood: a matched-pair analysis. J. Clin. Oncol. 19, 3188-3193.
7. Ossenkoppele, G. J., Stam, A. G., Westers, T. M., de Gruijl, T. D., Janssen, J. J., van de Loosdrecht, A. A., Scheper, R. J. (2003) Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia 17, 1424-1426.
8. Claxton, D., Kao, S. F. (2003) Autologous immunotherapy for human leukemias. Blood Cells Mol. Dis. 31, 121-124.
9. Kochenderfer, J. N., Molldrem, J. J. (2001) Leukemia vaccines. Curr. Oncol. Rep. 3, 193-200.
10. Cignetti, A., Vallario, A., Roato, I., Circosta, P., Allione, B., Casorzo, L., Ghia, P., Caligaris-Cappio, F. (2004) Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. J. Immunol. 173, 2855-2865.
11. Houtenbos, I., Westers, T. M., Ossenkoppele, G. J., van de Loosdrecht, A. A. (2006) Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia. Haematologica 91, 348-355.
12. Yotnda, P., Garcia, F., Peuchmaur, M., Grandchamp, B., Duval, M., Lemonnier, F., Vilmer, E., Langlade-Demoyen, P. (1998) Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J. Clin. Invest. 102, 455-462.
13. Gelmetti, V., Zhang, J., Fanelli, M., Minucci, S., Pelicci, P. G., Lazar, M. A. (1998) Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol. Cell. Biol. 18, 7185-7191.
14. Amann, J. M., Nip, J., Strom, D. K., Lutterbach, B., Harada, H., Lenny, N., Downing, J. R., Meyers, S., Hiebert, S. W. (2001) ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell. Biol. 21, 6470-6483.
15. Wang, L., Hiebert, S. W. (2001) TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3. Oncogene 20, 3716-3725.
16. Sambucetti, L. C., Fischer, D. D., Zabludoff, S., Kwon, P. O., Chamberlin, H., Trogani, N., Xu, H., Cohen, D. (1999) Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274, 34940-34947.
17. Downing, J. R. (1999) The AML1-ETO chimeric transcription factor in acute myeloid leukemia: biology and clinical significance. Br. J. Haematol. 106, 296-308.
18. Morrow, M., Horton, S., Kioussis, D., Brady, H. J., Williams, O. (2004) TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity. Blood 103, 3890-3896.
19. Wang, J., Saunthararajah, Y., Redner, R. L., Liu, J. M. (1999) Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res. 59, 2766-2769.
20. Gottlicher, M., Minucci, S., Zhu, P., Kramer, O. H., Schimpf, A., Giavara, S., Sleeman, J. P., Lo Coco, F., Nervi, C., Pelicci, P. G., Heinzel, T. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978.
21. Kitamura, K., Hoshi, S., Koike, M., Kiyoi, H., Saito, H., Naoe, T. (2000) Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. Br. J. Haematol. 108, 696-702.
22. Rosato, R. R., Almenara, J. A., Grant, S. (2003) The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 63, 3637-3645.
23. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., Nakanishi, O. (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 96, 4592-4597.
24. Marks, P., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., Kelly, W. K. (2001) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1, 194-202.
25. Nimmanapalli, R., Fuino, L., Stobaugh, C., Richon, V., Bhalla, K. (2003) Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101, 3236-3239.
26. Klisovic, M. I., Maghraby, E. A., Parthun, M. R., Guimond, M., Sklenar, A. R., Whitman, S. P., Chan, K. K., Murphy, T., Anon, J., Archer, K. J., Rush, L. J., Plass, C., Grever, M. R., Byrd, J. C., Marcucci, G. (2003) Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 17, 350 -358.
27. Yu, C., Rahmani, M., Almenara, J., Subler, M., Krystal, G., Conrad, D., Varticovski, L., Dent, P., Grant, S. (2003) Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res. 63, 2118-2126.
28. Starkova, J., Madzo, J., Cario, G., Kalina, T., Ford, A., Zaliova, M., Hrusak, O., Trka, J. (2007) The identification of (ETV6)/RUNX1-regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6/RUNX1-positive lymphoid leukemic cells. Clin. Cancer Res. 13, 1726 -1735.
29. Moldenhauer, A., Frank, R. C., Pinilla-Ibarz, J., Holland, G., Boccuni, P., Scheinberg, D. A., Salama, A., Seeger, K., Moore, M. A., Nimer, S. D. (2004) Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. J. Leukoc. Biol. 76, 623-633.
30. Bartoli, A., Fettucciari, K., Fetriconi, I., Rosati, E., Ianni, M. D., Tabilio, A., Delfino, D. V., Rossi, R., Marconi, P. (2003) Effect of trichostatin a and 5'-azacytidine on transgene reactivation in U937 transduced cells. Pharmacol. Res. 48, 111-118.
31. Minucci, S., Pelicci, P. G. (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51.
32. Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W. G., Faderl, S., Koller, C., Morris, G., Rosner, G., Loboda, A., Fantin, V. R., Randolph, S. S., Hardwick, J. S., Reilly, J. F., Chen, C., Ricker, J. L., Seerist, J. P., Richon, V. M., Frankel, S. R., Kantarjian, H. M. (2008) Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111, 1060-1066.
33. Bug, G., Schwarz, K., Schoch, C., Kampfmann, M., Henschler, R., Hoel-zer, D., Ottmann, O. G., Ruthardt, M. (2007) Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica 92, 542-545.
34. Kuendgen, A., Schmid, M., Schlenk, R., Knipp, S., Hildebrandt, B., Steidl, C., Germing, U., Haas, R., Dohner, H., Gattermann, N. (2006) The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106, 112-119.
35. Raffoux, E., Chaibi, P., Dombret, H., Degos, L. (2005) Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 90, 986 -988.
36. Moldenhauer, A., Nociari, M. M., Dias, S., Lalezari, P., Moore, M. A. (2003) Optimized culture conditions for the generation of dendritic cells from peripheral blood monocytes. Vox Sang. 84, 228-236.
37. Seeger, K., Kreuzer, K. A., Lass, U., Taube, T., Buchwald, D., Eckert, C., Korner, G., Schmidt, C. A., Henze, G. (2001) Molecular quantification of response to therapy and remission status in TEL-AML1-positive childhood ALL by real-time reverse transcription polymerase chain reaction. Cancer Res. 61, 2517-2522.
38. Yun, C., Senju, S., Fujita, H., Tsuji, Y., Irie, A., Matsushita, S., Nish-imura, Y. (1999) Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. Tissue Antigens 54, 153-161.
39. Letsch, A., Scheibenbogen, C. (2003) Quantification and characterization of specific T-cells by antigen-specific cytokine production using ELISPOT assay or intracellular cytokine staining. Methods 31, 143-149.
40. Schrappe, M. (2004) Evolution of BFM trials for childhood ALL. Ann. Hematol. 83 (Suppl. 1), S121-S123.
41. Graubner, U. B., Porzig, S., Jorch, N., Kolb, R., Wessalowski, R., Es-cherich, G., Janka, G. E. (2008) Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer 50, 259-263.
42. Reiter, A. (2004) B-NHL BFM 04. Multizentrische beobachtungsstudie zur behandlung von kindern und jugendlichen mit reifem B-cell non-Hodgkin lymphom oder B-ALL. In Gesellschaft fuer Paediatrische Inkologie und Haematologie (GPOH), Giessen, Germany.
43. Stanulla, M., Schaeffeler, E., Flohr, T., Cario, G., Schrauder, A., Zimmer-mann, M., Welte, K., Ludwig, W. D., Bartram, C. R., Zanger, U. M., Eichelbaum, M., Schrappe, M., Schwab, M. (2005) Thiopurine methyl-transferase (TPMT) genotype and early treatment response to mercapto-purine in childhood acute lymphoblastic leukemia. JAMA 293, 1485-1489.
44. Seeger, K., Adams, H. P., Buchwald, D., Beyermann, B., Kremens, B., Niemeyer, C., Ritter, J., Schwabe, D., Harms, D., Schrappe, M., Henze, G. (1998) TEL-AML1 fusion transcript in relapsed childhood acute lympho-blastic leukemia. The Berlin-Frankfurt-Munster Study Group. Blood 91, 1716 -1722.
45. Hangoc, G., Broxmeyer, H. E. (1989) Effects of purified recombinant human interleukin-3 on the growth of human hematopoietic progenitor cells in "long-term" bone marrow culture. Biotechnol. Ther. 1, 17-29.
46. Morse, M. A., Zhou, L. J., Tedder, T. F., Lyerly, H. K., Smith, C. (1997) Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleu-kin-4, and tumor necrosis factor-α for use in cancer immunotherapy. Ann. Surg. 226, 6-16.
47. Lauener, R. P., Goyert, S. M., Geha, R. S., Vercelli, D. (1990) Interleukin 4 down-regulates the expression of CD14 in normal human monocytes. Eur. J. Immunol. 20, 2375-2381.
48. Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D., Gabrilovich, D. I. (1998) Vascular endothelial growth factor affects dendritic cell maturation through inhibition of nuclear factor-ΚB activation in hemato-poietic progenitor cells. J. Immunol. 160, 1224-1232.
49. Jansen, J. H., Wientjens, G. H. M., Fibbe, W. E., Willemze, R., Kluin-Nelemans, H. C. (1989) Inhibition of human macrophage colony formation by interleukin 4. J. Exp. Med. 170, 577-582.
50. Hart, D. N. J. (1997) Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90, 3245-3287.
51. Zhou, L. J., Tedder, T. F. (1995) Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol. 154, 3821-3835.
52. Banchereau, J., Steinman, R. M. (1998) Dendritic cells and the control of immunity. Nature 392, 245-252.
53. Westers, T. M., Stam, A. G., Scheper, R. J., Regelink, J. C., Nieuwint, A. W., Schuurhuis, G. J., van de Loosdrecht, A. A., Ossenkoppele, G. J. (2003) Rapid generation of antigen-presenting cells from leukemic blasts in acute myeloid leukemia. Cancer Immunol. Immunother. 52, 17-27.
54. Kohler, T., Plettig, R., Wetzstein, W., Schmitz, M., Ritter, M., Mohr, B., Schaekel, U., Ehninger, G., Bornhauser, M. (2000) Cytokine-driven differentiation of blasts from patients with acute myelogenous and lympho-blastic leukemia into dendritic cells. Stem Cells 18, 139 -147.
55. Harrison, B. D., Adams, J. A., Briggs, M., Brereton, M. L., Yin, J. A. (2001) Stimulation of autologous proliferative and cytotoxic T-cell responses by "leukemic dendritic cells" derived from blast cells in acute myeloid leukemia. Blood 97, 2764-2771.
56. Blair, A., Rowbottom, A. W., Browne, S. J., Goulden, N. J., Steward, C. G., Oakhill, A., Pamphilon, D. H. (2001) An optimized biphasic culture system for the generation of functional dendritic cells from patients with acute lymphoblastic leukemia at presentation and in clinical remission. Leukemia 15, 1596-1603.
57. Wilkes, G. (2007) Histone deacetylase inhibitors. Oncology 21, 39-40.
58. Bruserud, O., Stapnes, C., Ersvaer, E., Gjertsen, B. T., Ryningen, A. (2007) Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr. Pharm. Biotechnol. 8, 388-400.
59. Budillon, A., Di Gennaro, E., Bruzzese, F., Rocco, M., Manzo, G., Caraglia, M. (2007) Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents. Recent Patents Anticancer Drug Discov. 2, 119 -134.
60. Maeda, T., Towatari, M., Kosugi, H., Saito, H. (2000) Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96, 3847-3856.
61. Reddy, P., Zou, W. (2007) Blocking HDACs boosts regulatory T cells. Nat. Med. 13, 1282-1284.
62. Tao, R., de Zoeten, E. F., Ozkaynak, E., Chen, C., Wang, L., Porrett, P. M., Li, B., Turka, L. A., Olson, E. N., Greene, M. I., Wells, A. D., Hancock, W. W. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13, 1299-1307.
63. Edens, R. E., Dagtas, S., Gilbert, K. M. (2006) Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. Int. Immunopharmacol. 6, 1673-1681.
64. Spisek, R., Chevallier, P., Morineau, N., Milpied, N., Avet-Loiseau, H., Harousseau, J. L., Meflah, K., Gregoire, M. (2002) Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res. 62, 2861-2868.
65. Rosenblatt, J., Avigan, D. (2006) Can leukemia-derived dendritic cells generate antileukemia immunity? Expert Rev. Vaccines 5, 467-472.
66. Moldenhauer, A., Moore, M. A., Schmidt, K., Kiesewetter, H., Salama, A. (2006) Differences in the transmigration of different dendritic cells. Exp. Hematol. 34, 745-752.
67. Zuna, J., Krejci, O., Madzo, J., Fronkova, E., Sramkova, L., Hrusak, O., Kalina, T., Vaskova, M., Stary, J., Trka, J. (2005) TEL/AML1 and immu-noreceptor gene rearrangements-which comes first? Leuk. Res. 29, 633-639.
68. Palucka, A. K., Ueno, H., Fay, J. W., Banchereau, J. (2007) Taming cancer by inducing immunity via dendritic cells. Immunol. Rev. 220, 129 -150.
69. Bedrosian, I., Mick, R., Xu, S., Nisenbaum, H., Faries, M., Zhang, P., Cohen, P. A., Koski, G., Czerniecki, B. J. (2003) Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8 + T-cell function in melanoma patients. J. Clin. Oncol. 21, 3826-3835.